Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 Nanotech Investing
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation Nanotech Investing
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors Nanotech Investing
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules Nanotech Investing
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference Nanotech Investing
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program Nanotech Investing
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma Nanotech Investing
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Nanotech Investing
dynaCERT Expands into the Port Market: French Port Equips Crane Fleet with HydraGEN Cleantech Investing
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET Nanotech Investing
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy Nanotech Investing
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 Nanotech Investing
